## Nandu Thalange

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1401506/publications.pdf

Version: 2024-02-01

623188 28 686 14 citations h-index papers

25 g-index 28 28 28 981 docs citations times ranked citing authors all docs

580395

#	Article	IF	CITATIONS
1	Artificial intelligence in the endocrine clinic: automated bone age analysis in arabic children from UAE. Medical Science and Discovery, 2021, 8, 418-422.	0.1	O
2	Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes. Clinical Diabetes, 2021, 39, 347-357.	1.2	9
3	The rate of hyperglycemia and ketosis with insulin degludecâ€based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatric Diabetes, 2019, 20, 314-320.	1.2	12
4	Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports. Diabetes Therapy, 2019, 10, 1219-1237.	1.2	2
5	Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. BMJ Open Diabetes Research and Care, 2019, 7, e000664.	1.2	7
6	A longitudinal, observational study examining the relationships of patient satisfaction with services and mental wellâ€being to their clinical course in young people with Type 1 diabetes mellitus during transition from child to adult health services. Diabetic Medicine, 2018, 35, 1216-1222.	1.2	8
7	Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT). Diabetes Care, 2018, 41, 1963-1969.	4.3	27
8	Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK. Diabetes Therapy, 2017, 8, 1065-1078.	1.2	3
9	Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16ÂYears. Diabetes Therapy, 2016, 7, 713-724.	1.2	4
10	Weightâ€sparing effect of insulin detemir: a consequence of central nervous systemâ€mediated reduced energy intake?. Diabetes, Obesity and Metabolism, 2015, 17, 919-927.	2.2	25
11	Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatric Diabetes, 2015, 16, 164-176.	1.2	74
12	Insulin analogues in children with TypeÂ1 diabetes: a 52â€week randomized clinical trial. Diabetic Medicine, 2013, 30, 216-225.	1.2	31
13	Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus. Pediatric Diabetes, 2011, 12, 632-641.	1.2	18
14	Short-Term Growth in Children with Congenital Adrenal Hyperplasia. Hormone Research, 2009, 71, 142-147.	1.8	6
15	Post-traumatic stress symptoms in mothers of very low birth weight infants 2–3Âyears post-partum. Archives of Women's Mental Health, 2009, 12, 261-264.	1.2	49
16	Blood pressure centiles for Great Britain. Archives of Disease in Childhood, 2007, 92, 298-303.	1.0	177
17	Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance. Journal of Endocrinological Investigation, 2007, 30, 439-441.	1.8	2
18	Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. European Journal of Pediatrics, 2007, 166, 585-588.	1.3	22

#	Article	IF	CITATIONS
19	Growth deficiency in oculodigitoesophagoduodenal (Feingold) syndrome ??? case report and review of the literature. Clinical Dysmorphology, 2005, 14, 155-158.	0.1	6
20	Growth deficiency in oculodigitoesophagoduodenal (Feingold) syndrome-case report and review of the literature. Clinical Dysmorphology, 2005, 14, 155-158.	0.1	0
21	How is money spent on children's services?. Child: Care, Health and Development, 2004, 30, 503-505.	0.8	1
22	Public health: The Anglia Public Health Fellowship—an innovative training opportunity. Archives of Disease in Childhood, 2000, 83, 375-376.	1.0	0
23	Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal children. Growth Hormone and IGF Research, 2000, 10, 28-36.	0.5	27
24	Regular fluctuations in growth hormone (GH) release determine normal human growth. Growth Hormone and IGF Research, 1999, 9, 114-122.	0.5	18
25	The Relationship Between Stature, Growth, and Short-term Changes in Height and Weight in Normal Prepubertal Children. Pediatric Research, 1998, 44, 882-886.	1.1	48
26	Model of normal prepubertal growth Archives of Disease in Childhood, 1996, 75, 427-431.	1.0	57
27	Insulin-Like Growth Factor Binding Protein-3 Generation: An Index of Growth Hormone Insensitivity. Pediatric Research, 1996, 39, 849-855.	1.1	38
28	Infradian rhythms in urinary growth hormone excretion. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 100-106.	1.8	15